IGC Pharma, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
IGC$0.20-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’EQUITY
| Three months ended June 30, 2025 | Number of Common Shares | Common Stock and Additional Paid in Capital ($) | Accumulated Deficit ($) | Accumulated Other Comprehensive Loss ($) | Total Stockholders’ Equity ($) |
|---|---|---|---|---|---|
| Balances as of March 31, 2025 | 80,878 | 130,570 | (120,744) | (3,496) | 6,330 |
| Common stock-based compensation & expenses, net | - | 498 | - | - | 498 |
| Common stock subscribed but not yet issued | - | 13 | - | - | 13 |
| Issuance of common stock through offering (net of expenses) | 3,263 | 839 | - | - | 839 |
| Cancellation/forfeiture of shares | - | - | - | - | - |
| Net loss | - | - | (1,599) | - | (1,599) |
| Foreign currency translation adjustments | - | - | - | (3) | (3) |
| Balances as of June 30, 2025 | 84,141 | 131,920 | (122,343) | (3,499) | 6,078 |
| Balances as of March 31, 2026 | 98,796 | 139,122 | (127,292) | (5,709) | 6,121 |
| Common stock-based compensation & expenses, net | - | 750 | - | - | 750 |
| Common stock subscribed but not yet issued | - | 1,154 | - | - | 1,154 |
| Issuance of common stock through offering (net of expenses) | 3,621 | 1,039 | - | - | 1,039 |
| Cancellation/forfeiture of shares | - | - | - | - | - |
| Net loss | - | - | (2,936) | - | (2,936) |
| Foreign currency translation adjustments | - | - | - | 4 | 4 |
| Balances as of June 30, 2026 | 102,417 | 142,065 | (130,228) | (5,705) | 6,132 |
| Six months ended June 30, 2025 | Number of Common Shares | Common Stock and Additional Paid in Capital ($) | Accumulated Deficit ($) | Accumulated Other Comprehensive Loss ($) | Total Stockholders’ Equity ($) |
|---|---|---|---|---|---|
| Balances as of December 31, 2024 | 78,203 | 129,307 | (119,589) | (3,459) | 6,259 |
| Common stock-based compensation & expenses, net | - | 956 | - | - | 956 |
| Common stock subscribed but not yet issued | - | 13 | - | - | 13 |
| Issuance of common stock through offering (net of expenses) | 5,938 | 1,644 | - | - | 1,644 |
| Other adjustments | - | - | 43 | (43) | - |
| Cancellation/forfeiture of shares | - | - | - | - | - |
| Net loss | - | - | (2,797) | - | (2,797) |
| Foreign currency translation adjustments | - | - | - | 3 | 3 |
| Balances as of June 30, 2025 | 84,141 | 131,920 | (122,343) | (3,499) | 6,078 |
| Balances as of December 31, 2025 | 95,038 | 138,014 | (124,890) | (5,701) | 7,423 |
| Common stock-based compensation & expenses, net | 2,357 | 1,771 | - | - | 1,771 |
| Common stock subscribed but not yet issued | - | 890 | - | - | 890 |
| Issuance of common stock through offering (net of expenses) | 5,022 | 1,390 | - | - | 1,390 |
| Cancellation/forfeiture of shares | - | - | - | - | - |
| Net loss | - | - | (5,338) | - | (5,338) |
| Foreign currency translation adjustments | - | - | - | (4) | (4) |
| Balances as of June 30, 2026 | 102,417 | 142,065 | (130,228) | (5,705) | 6,132 |
| June 30, 2026, Form 10-Q
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.